The most common side effects of pioglitazone are fluid retention (edema), weight gain, and an increased risk of bone fractures. These three effects occur frequently enough that most people taking the medication will experience at least one of them. Less common but more serious concerns include heart failure, vision changes, and a small increase in bladder cancer risk with long-term use.
Fluid Retention and Swelling
Swelling, particularly in the legs and feet, is the side effect you’re most likely to notice. In clinical trials, about 4.8% of people taking pioglitazone alone developed edema, compared to just 1.2% on a placebo. That number climbs significantly when pioglitazone is paired with other diabetes medications. Combined with a sulfonylurea, edema rates reached 7.5%. Combined with metformin, 6.0%. And when taken alongside insulin, the rate jumped to 15.3%, roughly double the rate seen with insulin alone.
The swelling happens because pioglitazone changes how your kidneys handle sodium. Your body retains more salt and water than usual, expanding your blood volume. The medication also appears to make blood vessels more permeable, allowing fluid to leak into surrounding tissues. This is why the swelling tends to concentrate in your lower legs and ankles, where gravity pulls that extra fluid.
Weight Gain
Weight gain with pioglitazone is gradual and dose-dependent. In clinical studies, people gained an average of about 1.7 kg (roughly 3.7 pounds) after three months and 3.9 kg (about 8.5 pounds) after six months. The range varies widely depending on dose and whether you’re taking other diabetes medications. On pioglitazone alone, weight gain ranged from 0.3 to 3.6 kg. In combination therapy, it ranged from 0.9 to 5.5 kg.
Part of this weight comes from the fluid retention described above, but not all of it. Pioglitazone activates a receptor in your cells that ramps up fat storage. Specifically, it increases the activity of genes that help fat cells absorb and hold onto fatty acids. This means you’re genuinely gaining fat tissue, not just water weight. The effect is more pronounced at higher doses (30 to 45 mg daily versus 15 mg). Some research has shown that pairing pioglitazone with a structured portion-control diet can blunt the weight gain, so dietary choices during treatment do make a meaningful difference.
Bone Fracture Risk
Pioglitazone weakens bones over time, and this effect is particularly concerning for women. In clinical data, fracture rates were 1.9 per 100 patient-years in women taking pioglitazone, compared to 1.1 per 100 patient-years in those on other treatments. That works out to roughly 0.8 extra fractures per 100 women per year of use.
The fractures don’t typically occur in the spine or hip, which are the classic osteoporosis sites. Instead, they concentrate in the forearm, wrist, hand, foot, ankle, and shin. These are the kinds of breaks that happen from relatively minor falls or impacts, suggesting that pioglitazone reduces bone density enough to make everyday injuries more damaging. If you’re a postmenopausal woman or already have risk factors for osteoporosis, this side effect deserves a conversation with your prescriber.
Heart Failure Risk
Pioglitazone carries an FDA black box warning for congestive heart failure, the agency’s most serious safety label. The fluid retention caused by the drug can overload the heart in susceptible people, forcing it to work harder to pump the extra volume. Across real-world patient registries, the relative risk of heart failure with pioglitazone ranged from 1.06 to 1.76 compared to treatments without it. When combined with insulin, the risk ranged from 1.10 to 1.44.
The medication is outright contraindicated if you have moderate to severe heart failure (classified as NYHA Class III or IV, meaning symptoms that limit your physical activity or occur at rest). For everyone else, the FDA recommends watching for warning signs after starting the drug or increasing the dose. Rapid weight gain over a short period, shortness of breath, and new or worsening swelling in the legs are all signals that fluid buildup may be stressing the heart.
Vision Changes From Macular Edema
The same fluid retention that causes leg swelling can also affect the eyes. Pioglitazone is associated with macular edema, a condition where fluid accumulates in the central part of the retina. A large observational study of 170,000 patients found that those taking pioglitazone or related drugs were 1.6 times more likely to develop diabetic macular edema after adjusting for age, blood sugar control, and insulin use.
Symptoms include blurry or distorted vision and difficulty reading or seeing fine details. Because people with type 2 diabetes are already at higher risk for eye problems, any new visual changes while taking pioglitazone should prompt an eye exam. Macular edema from the medication typically improves if the drug is stopped.
Low Blood Sugar in Combination Therapy
On its own, pioglitazone rarely causes low blood sugar. Unlike some diabetes medications, it doesn’t stimulate your pancreas to release more insulin. Instead, it makes your cells more responsive to the insulin you already produce. This means your blood sugar won’t drop below normal levels from pioglitazone alone.
The picture changes when you combine it with insulin or sulfonylureas, which do actively push blood sugar down. The improved insulin sensitivity from pioglitazone amplifies their effect, and hypoglycemia becomes a real possibility. If low blood sugar episodes start occurring on combination therapy, the usual approach is to reduce the dose of insulin or the sulfonylurea rather than stopping pioglitazone.
Bladder Cancer With Long-Term Use
A systematic review and meta-analysis found that people who had ever used pioglitazone had a 13% higher risk of bladder cancer compared to those who never took it. That’s a modest increase in absolute terms, but the risk grows with longer use and higher cumulative doses. For people who took pioglitazone for more than two years, the risk was 49% higher. At cumulative doses above 28 grams (equivalent to years of daily use at typical doses), the risk was 66% higher. Use for less than one year showed no statistically significant increase.
This finding led several countries to restrict or suspend pioglitazone sales, though it remains available in the United States and many other markets. If you notice blood in your urine while taking pioglitazone, that warrants prompt evaluation, though blood in the urine has many causes unrelated to cancer.
Liver Monitoring
Pioglitazone requires liver function testing before you start and at least once a year while you’re on it. The drug should not be started if your liver enzyme levels are more than 2.5 times the upper limit of normal. If annual monitoring shows levels exceeding three times normal, the medication is typically discontinued. Liver toxicity was a serious problem with an older drug in the same class (troglitazone, which was pulled from the market), and while pioglitazone has a much better liver safety profile, routine monitoring remains standard practice.
A mild drop in red blood cell counts (measured as hematocrit and hemoglobin) can also occur. This is generally a dilution effect from the increased fluid volume rather than a true decrease in red blood cell production, and it rarely causes symptoms on its own.